What's in Main Line Center for Laser Surgery's pipeline?

Main Line Center for Laser Surgery has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Main Line Center for Laser Surgery's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/main-line-center-for-laser-surgery.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Main Line Center for Laser Surgery — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Main Line Center for Laser Surgery pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
DaxibotulinumtoxinA 20 units	DaxibotulinumtoxinA 20 units	marketed
Radiesse, Xeomin, Belotero	Radiesse, Xeomin, Belotero	marketed	Dermal fillers and neurotoxin		Dermatology/Aesthetics

Therapeutic area mix

Dermatology/Aesthetics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Main Line Center for Laser Surgery:

Cite this brief

Drug Landscape (2026). Main Line Center for Laser Surgery — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/main-line-center-for-laser-surgery. Accessed 2026-05-17.